|
Mental deterioration
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We aimed to explore the critical structural alterations in the process of cognitive decline and its relationships with the dopaminergic deficit and the level of related cerebrospinal fluid (CSF) proteins.
|
31278861 |
2020 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additionally, we tried to identify a cerebrospinal fluid (CSF) biomarker correlated with the degree and rate of cognitive decline in progressive MS patients.
|
31802039 |
2020 |
|
Mental deterioration
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We included 63 individuals with subjective cognitive decline (age 64 ± 8, MMSE 29 ± 1), with amyloid status (positron emission tomography [PET] scans n = 59, or Aβ<sub>1-42</sub> cerebrospinal fluid [CSF] n = 4).
|
31075283 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The finding that amnestic MCI based on brief neuropsychological assessment is significantly associated with CSF biomarkers for cognitive decline and Alzheimer's disease is in accordance with longitudinal studies that find memory impairment; both in itself and especially in combination with other cognitive deficit to constitute a risk factor for subsequent cognitive decline and dementia.
|
30614807 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
3446 individuals (1154 AD cases and 2292 controls) were included in the analyses of AD risk, 1400 individuals (cognitively normal = 747, AD = 653) in the CSF biomarker analyses, and 861 individuals in the analyses of cognitive decline.
|
30792413 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Surgical goals for this patient included the following: 1) removal of potentially epileptogenic and dysfunctional tissue; 2) preservation of cranial nerves; 3) prevention of cognitive decline or iatrogenic deficit; 4) prevention of CSF leak; 5) reconstruction of skull base; 6) prevention of airway and swallowing compromise; and 7) cosmesis.
|
31628278 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
All patients completed neuropsychological tests, core CSF AD biomarkers assessment (Aβ<sub>1-42</sub>, total tau, and phosphorylated tau), and follow-up for a mean of 3 years to verify cognitive decline.
|
30317034 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Elevated baseline plasma NfL is a prognostic marker of cognitive decline and neuroimaging measures of neurodegeneration, and has similar effect sizes to baseline CSF NfL.
|
31182505 |
2019 |
|
Mental deterioration
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We included 768 patients (194 with subjective cognitive decline (SCD), 127 mild cognitive impairment (MCI), 309 Alzheimer's dementia (AD), and 138 non-AD) who were categorized as concordant-negative (n = 315, 41%), discordant (n = 97, 13%), or concordant-positive (n = 356, 46%) based on CSF and PET results.
|
31511058 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Taking advantage of repeated amyloid PET and CSF measures, this dynamic view offers new insight into the progression of Alzheimer's disease biomarkers and their relationships with cognitive decline.
|
31350262 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This study indicates that Amyloid-PET and CSF biomarkers might not reflect identical clinical information and a combination of both seems to be the most accurate way to characterize clinically unclear cognitive decline.
|
30735665 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To investigate, if a potentially reduced CSF flow due to the giant arachnoid cyst contributed to the early manifestation of AD, we reviewed 15 case series of subjects with frontotemporal arachnoid cysts and cognitive decline.
|
31488095 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These findings confirm previous reports of low CSF Aβ42, elevated CSF total tau and reduced dopaminergic integrity being associated with cognitive decline in PD.
|
30820739 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Elevated CSF cortisol may also be associated with a more rapid cognitive decline in MCI due to AD.
|
30881301 |
2019 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Subanalysis of the separate diagnostic groups demonstrated significant correlations between CSF biomarkers and generalized power and synchronization already in the subjective cognitive decline and mild cognitive impairment group.
|
29245058 |
2018 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The secondary goal was to determine the neuroimaging variables from MRI, FDG PET and CSF biomarkers that can predict future cognitive decline within each group.
|
29415470 |
2018 |
|
Mental deterioration
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
In an asymptomatic at-risk cohort, elevated CSF Aβ (with or without elevated tau) was associated with greater rates of cognitive decline, with the specific pattern of decline varying across cognitive measures.
|
29523644 |
2018 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The relationship of contactin-2 with cognitive decline (Mini-Mental State Examination (MMSE)) and other CSF biomarkers reflecting AD pathology were analyzed.
|
29859129 |
2018 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This is a secondary analysis of a previous study investigating CSF biomarkers, sleep impairment and cognitive decline in AD patients.
|
30372684 |
2018 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression.
|
29527163 |
2018 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CSF biomarkers like Amyloid beta 42, total tau and phosphorylated tau levels can be easily evaluated in individuals suffering from cognitive decline, to diagnose or exclude AD type dementia, since early stages.
|
28124618 |
2017 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CSF A<i>β</i>, <i>α</i>-synuclein, and neurogranin concentrations are related to cortical metabolism and cognitive decline.
|
29046879 |
2017 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To investigate whether concomitant Alzheimer's disease (AD) pathology, reflected by cerebrospinal fluid (CSF) biomarkers, has an impact on dementia with Lewy bodies (DLB) in terms of clinical presentation, cognitive decline, nursing home admittance and survival.
|
27794030 |
2017 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Baseline FDG-PET and episodic memory predict conversion to AD, whereas p-tau(181p)/Abeta(1-42) and, marginally, FDG-PET predict longitudinal cognitive decline.
|
20592257 |
2010 |